Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Crohn’s Disease Therapeutics Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Crohn’s Disease Therapeutics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Crohn’s Disease Therapeutics Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Crohn’s Disease Therapeutics Market: Type Movement Analysis, USD Million, 2023 & 2030
4.3. Non-Surgical
4.3.1. Non-Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.2. Immune System Suppressors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.3. Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.4. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Surgical
4.4.1. Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Crohn’s Disease Therapeutics Market: Route of Administration Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Crohn’s Disease Therapeutics Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
5.3. Injectable
5.3.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Oral
5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Crohn’s Disease Therapeutics Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Crohn’s Disease Therapeutics Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Crohn’s Disease Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Crohn’s Disease Therapeutics Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Crohn’s Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Takeda Pharmaceutical Company Limited
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/Strategic Initiatives
8.4.2. AbbVie Inc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/Strategic Initiatives
8.4.3. Perrigo Company plc
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/Strategic Initiatives
8.4.4. Pfizer Inc.
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/Strategic Initiatives
8.4.5. Johnson & Johnson Services Inc.
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/Strategic Initiatives
8.4.6. Ferring B.V.
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/Strategic Initiatives
8.4.7. Bristol-Myers Squibb Company (Celgene Corporation)
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/Strategic Initiatives
8.4.8. F. Hoffmann-La Roche Ltd (Genentech, Inc.)
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/Strategic Initiatives
8.4.9. UCB S.A.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/Strategic Initiatives
8.4.10. Salix Pharmaceuticals
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/Strategic Initiatives
8.4.11. Gilead Sciences Inc.
8.4.11.1. Participant’s Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Recent Developments/Strategic Initiatives